News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
250,097 Results
Type
Article (17589)
Company Profile (37)
Press Release (232471)
Section
Business (66536)
Career Advice (170)
Deals (10338)
Drug Delivery (29)
Drug Development (76217)
Employer Resources (12)
FDA (5752)
Job Trends (5409)
News (150916)
Policy (10523)
Tag
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (1)
2024 Genetown Standard (1)
2024 Pharm Country Digital (2)
Academia (832)
Accelerated approval (1)
Adcomms (19)
Allergies (58)
Alliances (17538)
ALS (66)
Alzheimer's disease (995)
Antibody-drug conjugate (ADC) (100)
Approvals (5746)
Artificial intelligence (78)
Autoimmune disease (16)
Automation (8)
Bankruptcy (77)
Best Places to Work (4695)
BIOSECURE Act (13)
Biosimilars (38)
Biotechnology (30)
Bladder cancer (57)
Brain cancer (22)
Breast cancer (201)
Cancer (1577)
Cardiovascular disease (118)
Career advice (151)
Career pathing (2)
CAR-T (110)
Cell therapy (273)
Cervical cancer (16)
Clinical research (66264)
Collaboration (367)
Compensation (140)
Complete response letters (22)
COVID-19 (1668)
CRISPR (30)
C-suite (96)
Cystic fibrosis (69)
Data (1523)
Decentralized trials (1)
Depression (36)
Diabetes (137)
Diagnostics (2023)
Digital health (3)
Diversity, equity & inclusion (7)
Drug discovery (56)
Drug pricing (13)
Drug shortages (2)
Duchenne muscular dystrophy (62)
Earnings (28609)
Editorial (11)
Employer branding (2)
Employer resources (12)
Events (37769)
Executive appointments (309)
FDA (6357)
Featured Employer (9)
Friedreich's ataxia (4)
Frontotemporal dementia (2)
Funding (340)
Gene editing (79)
Generative AI (8)
Gene therapy (180)
GLP-1 (527)
Government (1462)
Grass and pollen (1)
Guidances (16)
Healthcare (5375)
Huntington's disease (21)
IgA nephropathy (20)
Immunology and inflammation (92)
Indications (21)
Infectious disease (1752)
Inflammatory bowel disease (88)
Inflation Reduction Act (1)
Influenza (27)
Intellectual property (53)
Interviews (34)
IPO (5602)
IRA (3)
Job creations (990)
Job search strategy (130)
Kidney cancer (10)
Layoffs (271)
Legal (841)
Liver cancer (53)
Lung cancer (256)
Lymphoma (114)
Machine learning (1)
Management (1)
Manufacturing (100)
MASH (59)
Medical device (1465)
Medtech (1467)
Mergers & acquisitions (4921)
Metabolic disorders (435)
Multiple sclerosis (60)
NASH (21)
Neurodegenerative disease (80)
Neuropsychiatric disorders (28)
Neuroscience (1369)
NextGen: Class of 2025 (1398)
Non-profit (674)
Northern California (1464)
Now hiring (2)
Obesity (240)
Opinion (95)
Ovarian cancer (63)
Pain (49)
Pancreatic cancer (64)
Parkinson's disease (100)
Partnered (3)
Patents (81)
Patient recruitment (77)
Peanut (39)
People (18347)
Pharmaceutical (11)
Phase I (20703)
Phase II (30051)
Phase III (22460)
Pipeline (786)
Podcasts (21)
Policy (25)
Postmarket research (977)
Preclinical (4413)
Press Release (34)
Prostate cancer (69)
Psychedelics (32)
Radiopharmaceuticals (146)
Rare diseases (269)
Real estate (1475)
Recruiting (3)
Regulatory (9368)
Reports (10)
Research institute (1013)
Resumes & cover letters (21)
Rett syndrome (3)
RNA editing (2)
RSV (29)
Schizophrenia (60)
Series A (63)
Series B (54)
Sickle cell disease (35)
Southern California (1216)
Special edition (5)
Spinal muscular atrophy (109)
Sponsored (13)
Startups (1258)
Stomach cancer (11)
Supply chain (17)
The Weekly (21)
United States (10483)
Vaccines (435)
Venture capitalists (19)
Webinars (3)
Weight loss (157)
Women's health (7)
Date
Today (76)
Last 7 days (380)
Last 30 days (1445)
Last 365 days (18005)
2025 (4197)
2024 (18471)
2023 (20438)
2022 (23305)
2021 (24154)
2020 (20750)
2019 (14709)
2018 (11199)
2017 (13805)
2016 (12006)
2015 (14147)
2014 (9848)
2013 (7283)
2012 (7629)
2011 (8039)
2010 (7374)
Location
Africa (171)
Alabama (29)
Alaska (2)
Arizona (51)
Arkansas (3)
Asia (17550)
Australia (3175)
California (3171)
Canada (817)
China (312)
Colorado (74)
Connecticut (134)
Delaware (73)
Europe (40034)
Florida (355)
Georgia (89)
Idaho (12)
Illinois (146)
India (8)
Indiana (138)
Iowa (4)
Japan (102)
Kansas (37)
Kentucky (15)
Louisiana (2)
Maine (7)
Maryland (366)
Massachusetts (2076)
Michigan (51)
Minnesota (108)
Mississippi (1)
Missouri (30)
Montana (16)
Nebraska (9)
Nevada (35)
New Hampshire (9)
New Jersey (874)
New Mexico (14)
New York (867)
North Carolina (507)
North Dakota (6)
Northern California (1464)
Ohio (87)
Oklahoma (4)
Oregon (13)
Pennsylvania (599)
Puerto Rico (4)
Rhode Island (5)
South America (225)
South Carolina (3)
Southern California (1216)
Tennessee (14)
Texas (366)
Utah (62)
Virginia (57)
Washington D.C. (19)
Washington State (257)
Wisconsin (16)
250,097 Results for "phase genomics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Depression
Neumora Shakes Up Phase III MDD Trials After January Miss
After failing to hit the primary endpoint in a Phase III trial, Neumora is remixing study parameters in two replicate trials, with data expected in the first half of 2026.
March 3, 2025
·
1 min read
·
Dan Samorodnitsky
Neuropsychiatric disorders
Biohaven Disappoints Again, This Time in Phase II/III Bipolar Mania Trial
Biohaven in recent months has reported a clinical stumble in spinal muscular atrophy, alongside a Phase I readout for its protein degrader candidate that investors found underwhelming.
March 4, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Moss Genomics Announces Genomics Business Update, Integrating Blockchain for Genomic Security and Transparency
February 25, 2025
·
7 min read
Cancer
AstraZeneca Posts Positive Phase III Results for Oral Breast Cancer Drug
In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments in terms of progression-free survival, according to AstraZeneca.
February 26, 2025
·
1 min read
·
Dan Samorodnitsky
Obesity
Novo’s Studies of GLP-1s for Addiction Limited to Ongoing Phase II
Despite comments made by a Novo Nordisk official this week, the company confirmed to
BioSpace
that it has no additional clinical trials of its GLP-1 drugs in addiction beyond a Phase II trial testing semaglutide and two other drugs with alcohol use as a secondary endpoint.
March 7, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Ecotone Achieves Breakthrough in Human Genome Understanding with Novel AI Technology
AI-Powered Genomic Mapping Could Revolutionize Treatment of Rare Genetic Diseases
January 16, 2025
·
1 min read
Press Releases
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England
March 21, 2025
·
3 min read
Press Releases
CD Genomics Launches Innovative NGS-BSP to Enhance Genomic Understanding
March 27, 2025
·
1 min read
BioForest
Phase Genomics Announces Funding to Accelerate Discovery of New Lysin-Based Precision Antimicrobials
Phase Genomics, Inc. today announced $1.5MM in new funding from the Bill & Melinda Gates Foundation to fuel a new antimicrobial discovery platform.
March 5, 2024
·
3 min read
Business
Phase Genomics Announces Appointment of David Shoultz as First Chief Business Officer
October 9, 2024
·
2 min read
1 of 25,010
Next
